Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based developer and manufacturer of vaccines CSL has signed a commercial licensing deal with Selexis for a therapeutic antibody's preclinical development.
Subscribe to our email newsletter
Under the agreement, CSL has got the rights for using a cell line for the cGMP production of an undisclosed antibody.
The licensed cell line was generated by utilizing SUREtechnology Platform of Selexis.
Selexis’ SURE Cell Line Development Technology Platform is based on Selexis Genetic Elements- novel DNA-based elements that control the organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins.
Selexis CEO Igor Fisch said they look forward to continuing to work with CSL.